Maxim Group restated a buy rating and set a $23.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, November 2nd.
While looking at the Stock's Performance, Sucampo Pharmaceuticals, Inc. now shows a Weekly Performance of 3.62%, where Monthly Performance is 16.25%, Quarterly performance is 79.71%, 6 Months performance is 71.43% and yearly performance percentage is 39.33%.
The company has YTD performance of 0.56 percent.
A number of other brokerages have also recently weighed in on SCMP. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. They issued a buy rating and a $43.00 target price on the stock.
Chandigarh stalking case: Vikash Barla released from jail
Earlier this week on Tuesday, the cross examination of the victim Varnika Kundu concluded in the district courts in Chandigarh . His lawyer had moved the high court for regular bail in November after a local court denied him bail for the fourth time.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) gross margin percentage stands at 72.8% while its operating margin for the past trailing twelve month is -49.6 percent and its overall profit margin (ttm) is -60.2 Percent.
Sucampo Pharmaceuticals, Inc. (SCMP) stock is now trading 61.91% away from its average-price of 200 days while it maintained a distance of 37.32% from its 50 Days Moving Average and 7.43% compared with the 20 Day Moving Average. The rating was downgraded by Maxim Group on Tuesday, December 26 to "Hold". Finally, B. Riley started coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Sucampo Pharmaceuticals now has a consensus rating of "Buy" and an average price target of $17.33.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.35 during midday trading on Friday, hitting $18.05. The company has market cap of $847.29 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.20. This public company's current market capitalization stands at $862.96 million.
Spectrum Grp Inc Incorporated Inc holds 0% in Sucampo Pharmaceuticals, Inc. According to the Analysts, the Low Earnings estimate for the current quarter is $0.15, while the High earnings estimate is $0.26.Comparatively, EPS for the same quarter a year ago was $0.03. The company had revenue of $61.27 million during the quarter, compared to analysts' expectations of $58.05 million. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. On a percent-of-sales basis, SCMP's free cash flow was -0% while IONS converted 0% of its revenues into cash flow. During the same period in the prior year, the firm earned $0.30 EPS. research analysts anticipate that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year. And SharpCharts uses as a minimum 250 data points prior to the starting date of any chart (assuming that much data exists) at what time calculating its RSI values. Insiders own 4.13% of the company's stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Donald Trump Signals Openness to North Korea Diplomacy in Interview
It has, however, retained back-channel communications through the North's diplomatic mission at the United Nations in NY . Trump said in an interview Thursday with The Wall Street Journal . "I have relationships with people".
Growth isn't very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth. LSV Asset Management grew its stake in Sucampo Pharmaceuticals by 1.9% in the second quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company's stock valued at $25,099,000 after buying an additional 44,000 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Sucampo Pharmaceuticals in the second quarter valued at $117,000. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since January 12, 2017 and is downtrending. The average analysts gave this company a mean recommendation of 1.90. The company's institutional ownership is monitored at 74 percent.
Several hedge funds and other institutional investors have recently made changes to their positions in the company.
ILLEGAL ACTIVITY WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online.
Rockville, MD based Sucampo Pharmaceuticals, Inc.is a biopharmaceutical company. (NASDAQ: SCMP), a global biopharmaceutical company, today announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and development assets.
Battle Royale Mode to be Update with More Points of Interest
Fortnite's Battle Royale mode, for all the controversy that initially surrounded it , has found a solid footing within the genre. Epic says they have separated the map into what they say are more clearly defined biomes making each area feel more unique.